柳氮磺胺吡啶治疗强直性脊柱炎疗效分析

Therapeutic Anaiysis of Ankylosing Spondylitis with Sulfasalazine

  • 摘要: 对32例活动期强直性脊柱炎(AS)患者给予柳氮磺胺吡啶(Sulfasalazine,SSZ)治疗3~23月(第1周1.0/d,第2周起2.0/d维持),分别于服药后3月、6月及1年以上复查7项活动性指标(关节疼痛数、关节肿胀数、晨僵时间、扩胸度、Schober试验、ESR及CRP)。观察结果,治疗后除扩胸度以外的各项指标均显著改善;服药1年以上者临床缓解率显著高于服药3月或6月者;药物副作用多发生于服药3月内,本组患者无1例因副作用停药。结果表明SSZ对活动期AS患者具有肯定疗效,足够疗程与适当剂量对提高疗效具有重要意义。坚持服用SSZ(2.0/日)1年以上既可获得较高的临床缓解率又具有良好安全性。

     

    Abstract: cases with active ankylosing spondylitis (AS) were treated with sulfasalazine(SSZ) for 3 to 23 montlis. 3 months, 6 months and 1 year after taking medicine,7 active index-es were observed, including the number of painful and swelling joints, morning stiffness,Schobertest,chest expansive degree, ESR and CRP. The results showed the indexes were remarkably improved except chest expansive degree. In patients who took SSZ more than 1 year,the rateof clinical remission was marked higher compared with that for only 3 or 6 months. Side-effectsof ssz usually occured in the first 3 months of therapy, but no one case discontinued the thera-peutic course owing to the side-effects, The study indicated that SSZ had a sure efficacy intreating active AS. Sufficient duration and proper dosage were of important signifficance to incr-ease the therapeutic efficacy. Persisting in taking SSZ (2.0/d) over 1 year, the higher tate ofclinical remission and good security would be expected.

     

/

返回文章
返回